Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glucagon-like peptide-1 structure, function and potential use for NIDDM

D Gefel1, Y Barg, R Zimlichman

  • 1Department of Internal Medicine C, Barzilai Medical Center, Ashkelon, Israel.

Israel Journal of Medical Sciences
|December 16, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of the dual L- and T-type calcium channel blocker, ACT-280778: a proof-of-concept study in patients with mild-to-moderate essential hypertension.

Journal of human hypertension·2014
Same author

Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study.

Diabetic medicine : a journal of the British Diabetic Association·2007
Same author

High dose treatment with angiotensin II receptor blocker in patients with hypertension: differential effect of tissue protection versus blood pressure lowering.

Atherosclerosis·2007
Same author

C-reactive protein distribution and correlates among men and women with chronic coronary heart disease.

Cardiology·2007
Same author

Polycythemia as a result of ectopic erythropoietin production in benign cystic leiomyoma of uterus.

Acta obstetricia et gynecologica Scandinavica·2006
Same author

Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma.

Thyroid : official journal of the American Thyroid Association·2006

Glucagon-like peptide-1 (GLP-1) is an intestinal hormone that enhances insulin secretion. GLP-1 receptor agonists show promise for treating non-insulin-dependent diabetes mellitus (NIDDM).

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Metabolic Diseases

Background:

  • Proglucagon processing yields glucagon in the pancreas and glucagon-like peptide-1 (GLP-1) in the intestine.
  • GLP-1 and gastric inhibitory peptide (GIP) mediate the incretin effect, augmenting glucose-stimulated insulin secretion.
  • GLP-1 and GIP act via specific beta-cell receptors coupled to GTP-binding proteins.

Purpose of the Study:

  • To investigate the role of GLP-1 in insulin secretion and its potential therapeutic application in non-insulin-dependent diabetes mellitus (NIDDM).
  • To explore the hypothesis that GLP-1 receptor desensitization contributes to NIDDM pathogenesis.

Main Methods:

  • Analysis of proglucagon processing and hormone production.
  • Investigation of GLP-1 receptor signaling pathways in beta-cells.

Related Experiment Videos

  • Clinical studies involving GLP-1 infusion in NIDDM patients.

    • Main Results:

    • GLP-1 is released in response to food intake and enhances glucose-stimulated insulin secretion.
    • Desensitization of the GLP-1 receptor on beta-cells is proposed as a factor in NIDDM.
    • Pharmacological doses of GLP-1 improve postprandial insulin response in NIDDM patients.

    Conclusions:

    • GLP-1 plays a crucial role in regulating insulin secretion.
    • GLP-1 receptor agonists are potential therapeutic agents for NIDDM.
    • GLP-1 offers potential advantages over sulfonylurea drugs due to its glucose-dependent insulinotropic effects.